Nuvectis Pharma Q3 2026 net loss widens to $30.07 million
NVCT•Nuvectis Pharma’s third-quarter 2026 net loss widened to $30.07 million as research and development expenses rose to $27.37 million. Cash and cash equivalents totaled $140.71 million at September 30, with funding expected to support operations into the second half of 2029.
1. Quarterly results
Nuvectis Pharma’s third-quarter 2026 net loss widened to $30.07 million. Research and development expenses rose to $27.37 million, primarily driven by a $20 million upfront payment for NXP100 and NXP200 licensing.
2. Cash and milestones
Cash and cash equivalents reached $140.71 million at September 30, with funding expected to support operations into the second half of 2029. An FDA update on ciprocopan’s U.S. PNH pathway and U.S. IND submissions for NXP100 and NXP200 are expected by year-end.
